title: [Quamatel in the treatment of acute and chronic pancreatitis].
abstract: The aim of the study was to assess effects of H2-blocker of the IIId generation famotidine (quamatel) on the progression of acute and chronic pancreatitis and intensity of pain in patients with pancreatitis. 46 patients received standard therapy plus intravenous quamatel. Control patients received only standard treatment. It was found that intravenous quamatel relieves pain primarily within the first treatment week. Quamatel shortens duration of analgetics use, narcotic, in particular. It is thought valid to include quamatel in combined treatment of patients with acute and chronic pancreatitis.
authors.forename: E A
authors.initials: EA
authors.lastname: Belousova
authors.forename: A R
authors.initials: AR
authors.lastname: Zlatkin
authors.forename: I V
authors.initials: IV
authors.lastname: Nikulin
authors.forename: A I
authors.initials: AI
authors.lastname: Lovakov
authors.forename: V N
authors.initials: VN
authors.lastname: Filizhanko
authors.forename: E G
authors.initials: EG
authors.lastname: Shemeneva
authors.forename: M B
authors.initials: MB
authors.lastname: Dolgova
mesh_terms: D000208:Acute Disease; D000328:Adult; D002908:Chronic Disease; D018450:Disease Progression; D015738:Famotidine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010195:Pancreatitis / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D006635:Histamine H2 Antagonists; D015738:Famotidine